(function(){ var content_array=["

关于善可舒<\/strong>®<\/p> \n

善可舒®是格拉司琼透皮贴片,用于预防中度和\/或高度致吐性化疗引起的恶心和呕吐。每张52cm2<\/sup>的贴片含有34.3mg格拉司琼,每24小时释放3.1mg格拉司琼,释放长达7天。格拉司琼透皮贴片无创给药,疗效持久稳定,安全性良好8,9<\/sup>。目前,善可舒®已在包括美国、英国、德国、荷兰、西班牙、丹麦等22个国家和地区获批上市。2014年,在中国完成了临床药理学研究和一项随机、双盲、与口服格拉司琼对照的临床研究10<\/sup>。2018年7月,成功获得中国国家药品管理局(CNDA)的审批。<\/p> \n

关于苏爱康<\/strong><\/p> \n

苏爱康根植于亚洲,是一家致力为本地市场开发和销售创新肿瘤治疗药物及肿瘤支持治疗药物的制药公司。苏爱康关注亚洲肿瘤领域系统构建,开发肿瘤领域的创新药物,从日本和欧美领先的制药和生物技术公司引进优秀产品,并获得商业开发的许可,为中国及亚洲国家的病患带来健康福音。苏爱康积极回应患者与健康专业人员的需求,为改善患者生活,实现肿瘤领域突出且未满足的医疗需求而努力。有关苏爱康的更多信息请访问公司网站:www.solasia.com.cn<\/a>。<\/p> \n

\n \n \n \n

8. Boccia RV, Gordan LN, Clark G, et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011; 19(10): 1609-1617.
9. Kim JE, Hong YS, Lee JL, et al. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. Support Care Cancer. 2015; 23(6): 1769-1777.
10. Yang LQ, Sun XC, Qin SK, et al. Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study.  Chin Clin Oncol. 2016; 5(6): 79.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div>"]; $("#dvExtra").html(content_array[0]);})();